Clinical Trial Update: Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation [Phase 4]

View source ↗

Summary

A Phase 4 study completed evaluating the effect of tenapanor on the gut metagenome and metabolome in patients with irritable bowel syndrome with constipation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• IBSRELA (tenapanor hydrochloride)

Snippet

Sponsor: Kyle Staller, MD, MPH | Conditions: IBS, IBS - Irritable Bowel Syndrome | Phase 4 | Status: COMPLETED